Document Detail


Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study.
MedLine Citation:
PMID:  7831064     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Forty-four patients with intermittent claudication were included and randomised in two groups respectively treated with oral defibrotide (one 400 mg tablet bid) or oral mesoglycan (one 24 mg tablet bid) for 6 months. Twenty-two subjects completed the study in the defibrotide group and 20 in the mesoglycan group. The two treatments were well tolerated and the two drop outs in the mesoglycan group were not due to medical causes. In the defibrotide group, after 1 month the pain-free walking distance (PFWD) increased from 473 +/- 96 m to 586 +/- 84 (p < 0.05). The walking distance (WD) increased from 767 +/- 125 m to 898 +/- 109 (p < 0.05). After 6 months the posterior tibial pressure (PTP) at the end of the treadmill exercise test also increased from 40 +/- 19 to 63 +/- 12 (p < 0.05). No variations in PFWD, WD and PTP were observed in the mesoglycan group. The improvement in walking was possibly due to the action of defibrotide increasing local fibrinolysis and decreasing the distal vasospasm present in subjects with peripheral vascular disease and intermittent claudication.
Authors:
G Laurora; L Ambrosoli; M R Cesarone; M T De Sanctis; L Incandela; C Marelli; G Belcaro
Related Documents :
20433214 - The effect of exercise on haemodynamics in intermittent claudication: a systematic revi...
6729674 - The effect of exercise upon cutaneous oxygen delivery in the extremities of patients wi...
12762274 - Beneficial effects of exercise beyond the pain threshold in intermittent claudication.
19435644 - The influence of a long term exercise program on lower limb movement variability and wa...
23757424 - A single session of low-intensity exercise is sufficient to enhance insulin sensitivity...
23311814 - The role of weight training in treating farmers with lumbar discopathy.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Panminerva medica     Volume:  36     ISSN:  0031-0808     ISO Abbreviation:  Panminerva Med     Publication Date:  1994 Jun 
Date Detail:
Created Date:  1995-02-17     Completed Date:  1995-02-17     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0421110     Medline TA:  Panminerva Med     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  83-6     Citation Subset:  IM    
Affiliation:
Cardiovascular Institute, University of Chieti, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Double-Blind Method
Exercise Test
Exercise Tolerance / drug effects
Female
Fibrinolytic Agents / therapeutic use*
Glycosaminoglycans / therapeutic use*
Humans
Intermittent Claudication / drug therapy*
Male
Middle Aged
Polydeoxyribonucleotides / therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Glycosaminoglycans; 0/Polydeoxyribonucleotides; 438HCF2X0M/defibrotide; 80455-95-4/mesoglycan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The importance of vitamins in relation to the presence of heavy metals in food.
Next Document:  Acute effects of TTFCA on capillary filtration in severe venous hypertension.